» Articles » PMID: 22487523

Invasive Markers Identified by Gene Expression Profiling in Pancreatic Cancer

Overview
Journal Pancreatology
Date 2012 Apr 11
PMID 22487523
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Molecular profiling has proven utility as a diagnostic and predictive tool in clinical oncology. However, a clinically relevant gene expression profile in pancreatic cancer remains elusive.

Methods: Primary and metastatic pancreatic cancer cell lines (BxPC-3 and AsPC-1), were stimulated with phorbol-12-myristate 13-acetate (PMA), a known inducer of cell invasion. Affymetrix gene expression microarray analysis was performed, comparing gene expression to unstimulated controls. Differential expression was identified using ArrayAssist, and confirmed using quantitative real-time PCR. Bioinformatic analysis was performed using Pathway Studio and GOstat. The derived gene expression was further validated in fresh frozen pancreatic tumour samples. The ability of the derived 3 gene expression markersto differentiate between pancreatic adenocarcinoma (PDAC) and other neoplasms, and its association with clinicopathological variables was examined.

Results: PMA-induced significant changes in cell line gene expression, from which distinctive 3 potential invasive markers were derived. Expression of these genes, uPA, MMP-1 and IL1-R1 was confirmed in human pancreatic tumours, and was found to differentiate PDAC from other pancreatic neoplasms. The expression of IL1-R1 in PDAC is a novel finding. We found that the expression of MMP-1 was associated with high-grade PDAC (p = 0.035, Wilcoxon rank sum).

Conclusion: We have identified three potential invasive markers, uPA, MMP-1 and IL1-R1, whose gene expression may differentiate PDAC from other pancreatic neoplasms, and potentially reflect a more invasive phenotype.

Citing Articles

The Urokinase Plasminogen Activation System in Pancreatic Cancer: Prospective Diagnostic and Therapeutic Targets.

Kumar A, Buckley B, Ranson M Biomolecules. 2022; 12(2).

PMID: 35204653 PMC: 8961517. DOI: 10.3390/biom12020152.


High Matrix Metalloproteinase 28 Expression is Associated with Poor Prognosis in Pancreatic Adenocarcinoma.

Liu N, Zhong L, Ni G, Lin J, Xie L, Li T Onco Targets Ther. 2021; 14:4391-4406.

PMID: 34408436 PMC: 8364391. DOI: 10.2147/OTT.S309576.


Matrix Metalloproteases in Pancreatic Ductal Adenocarcinoma: Key Drivers of Disease Progression?.

Slapak E, Duitman J, Tekin C, Bijlsma M, Spek C Biology (Basel). 2020; 9(4).

PMID: 32325664 PMC: 7235986. DOI: 10.3390/biology9040080.


Acquired resistance of pancreatic cancer cells to cisplatin is multifactorial with cell context-dependent involvement of resistance genes.

Mezencev R, Matyunina L, Wagner G, McDonald J Cancer Gene Ther. 2016; 23(12):446-453.

PMID: 27910856 PMC: 5159445. DOI: 10.1038/cgt.2016.71.


The CaSm (LSm1) oncogene promotes transformation, chemoresistance and metastasis of pancreatic cancer cells.

Little E, Camp E, Wang C, Watson P, Watson D, Cole D Oncogenesis. 2016; 5:e182.

PMID: 26751936 PMC: 4728675. DOI: 10.1038/oncsis.2015.45.